What's in Takeshi Morimoto's pipeline?

Takeshi Morimoto has 4 drugs in our index: 4 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Takeshi Morimoto's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/takeshi-morimoto.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Takeshi Morimoto — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Takeshi Morimoto pipeline: 4 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Area
Goreisan	Goreisan	marketed	Other
12-month Edoxaban	12-month Edoxaban	marketed
Long DOAC	Long DOAC	marketed
No Carvedilol	No Carvedilol	marketed

Therapeutic area mix

Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Takeshi Morimoto:

Cite this brief

Drug Landscape (2026). Takeshi Morimoto — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/takeshi-morimoto. Accessed 2026-06-10.